To investigate the additive effect of Glo2 inhibition with a chemotherapeutic drug, we evaluated MCF7 cytotoxicity upon treatment with the doxorubicin (DOX), a commonly used anthracycline-class chemotherapy drug for treating breast cancer [27], testing six different concentrations for 24 and 48 h (Figure 5A). This evidence concerns the gene HAGH and breast carcinoma.